Bryan Johnson· Author
I take it because Rapamycin+Metformin ranks 10th best performing lifespan study. It raised median and 90th %ile wild type mouse lifespan by over 20% in both genders.
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
I take it because Rapamycin+Metformin ranks 10th best performing lifespan study. It raised median and 90th %ile wild type mouse lifespan by over 20% in both genders.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
i actually think that what might turn out to be the most helpful is combinations of these things so rapamycin plus metformin
it's the largest percent increase we've ever gotten and also it's the first time we've gotten an increase by combining two drugs together
I actually think that what might turn out to be the most helpful is combinations of these things so ramyon plus metformin
the ITP studies for Rapa always worked regardless of which which start young start old give it with met Foreman do it by itself always worked
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.